Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 12, 2023 16:05 ET | Source: SELLAS Life Sciences Group, Inc.

SELLAS Life Sciences Provides Update on Phase 3 REGAL Clinical Trial for Galinpepimut-S in Acute Myeloid Leukemia

- Enrollment ex-China Expected to be Completed in November 2023 – - Enrollment in China Expected to Commence this Quarter - NEW YORK, Oct. 12, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group,...
October 11, 2023 08:30 ET | Source: SELLAS Life Sciences Group, Inc.

SELLAS Announces First Patient Dosed in Phase Ib/II Trial of SLS009 (GFH009) in Relapsed/Refractory Peripheral T-cell Lymphomas

NEW YORK, Oct. 11, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of...
October 10, 2023 16:15 ET | Source: SELLAS Life Sciences Group, Inc.

SELLAS Receives FDA Orphan Drug Designation for SLS009 for Treatment of Acute Myeloid Leukemia

NEW YORK, Oct. 10, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of...
September 21, 2023 08:30 ET | Source: SELLAS Life Sciences Group, Inc.

SELLAS Announces Positive Topline Data in Lymphoma Cohort from SLS009 Phase 1 Dose-Escalation Trial, Supporting Advancement to Phase 2 Clinical Study; Primary and Secondary Endpoints Met

- 52 Relapsed and Refractory Lymphoma Patients Enrolled: 96% Alive at Last Assessment Indicating Favorable Survival Benefit - - Responses Observed Across Dose Levels with a 14.7% Clinical Response...
September 18, 2023 16:19 ET | Source: SELLAS Life Sciences Group, Inc.

SELLAS Life Sciences to Participate in the Cantor Fitzgerald Global Healthcare Conference

NEW YORK, Sept. 18, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) ("SELLAS" or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of...
August 22, 2023 08:30 ET | Source: SELLAS Life Sciences Group, Inc.

SELLAS Life Sciences Independent Data Monitoring Committee Recommends Galinpepimut-S REGAL Trial to Continue Without any Modifications

REGAL Interim Analysis Expected by Late 2023/Early 2024 Enrollment Expected to be Completed in Q4 2023 NEW YORK, Aug. 22, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS)...
August 10, 2023 16:08 ET | Source: SELLAS Life Sciences Group, Inc.

SELLAS Life Sciences Provides Business Update and Reports Second Quarter 2023 Financial Results

First Patients Dosed in Phase 2a Clinical Trial of SLS009 (formerly GFH009) in Acute Myeloid Leukemia with Topline Data Expected in 4Q 2023 Phase 3 REGAL Study of Galinpepimut-S in Patients with...
June 28, 2023 08:30 ET | Source: SELLAS Life Sciences Group, Inc.

SELLAS Life Sciences Reports Positive Data in Completed Phase 1 Study of Galinpepimut-S Combined with Opdivo® in Advanced Malignant Pleural Mesothelioma

Primary Endpoint of Safety and Efficacy Endpoint Both Met with Clinical Activity and Increased Survival Observed 70.3 Weeks Median Overall Survival for Patients Treated with Combination Therapy with...
June 22, 2023 08:45 ET | Source: SELLAS Life Sciences Group, Inc.

SELLAS Announces First Patient Dosed in Phase 2a Clinical Trial of GFH009 in Acute Myeloid Leukemia

NEW YORK, June 22, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of...
June 15, 2023 16:05 ET | Source: SELLAS Life Sciences Group, Inc.

SELLAS Life Sciences Announces Abstract Accepted for Presentation at International Gynecologic Cancer Society Annual Meeting

NEW YORK, June 15, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of...